Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

PGMS-pathway control state

From Bioblast
Revision as of 18:29, 17 March 2022 by Cardoso Luiza (talk | contribs) (Cardoso Luiza moved page PGMS pathway control state to PGMS-pathway control state: Edited to have same nomenclature used in other pages)
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)


high-resolution terminology - matching measurements at high-resolution


PGMS-pathway control state

Description

PGMS

PGMS: Pyruvate & Glutamate & Malate & Succinate.

MitoPathway control state: NS-pathway control state

2-oxoglutarate is produced through the citric acid cycle from citrate by isocitrate dehydrogenase, from oxaloacetate and glutamate by the transaminase, and from glutamate by the glutamate dehydrogenase. If the 2-oxoglutarate carrier does not outcompete these sources of 2-oxoglutarate, then the TCA cycle operates in full circle with external pyruvate&malate&glutamate&succinate

Abbreviation: PGMS

Reference: Gnaiger 2020 BEC MitoPathways

More details
Β» NS-pathway control state
Β» Additive effect of convergent electron flow
Β» Respiratory complexes - more than five
Β» Convergent electron flow


PGMSL

PGMS pathway in the LEAK state can be evaluated in the following SUIT protocols:


PGMSP

PGMS pathway in the OXPHOS state can be evaluated in the following SUIT protocols:

PGMSE

PGMS pathway in the ET state can be evaluated in the following SUIT protocols:

Discussion

Recent studies showed that S- and NS-linked OXPHOS capacity is inhibited by 2 mM malate concentrations as applied in many SUIT protocols. This inhibition is less pronounced at higher succinate concentrations (10 mM up to 50 mM S).


MitoPedia concepts: SUIT state